Minimal change disease

From Wikipedia, the free encyclopedia
  (Redirected from Lipoid nephrosis)
Jump to: navigation, search
Minimal change disease
Minimal Change Disease Pathology Diagram.svg
The three hallmarks of minimal change disease: diffuse loss of podocyte foot processes, vacuolation, and the appearance of microvilli.
Classification and external resources
Specialty urology
ICD-10 N00-N08 with .0 suffix
ICD-9-CM 581.3
DiseasesDB 8230
MedlinePlus 000496
eMedicine med/1483

Minimal change disease (MCD), also known as nil disease or by various other names, is a kidney disease that causes nephrotic syndrome and usually affects children (with peak incidence at ages 2 to 3 years).[1] The disease degrades the kidney's ability to filter, and the impaired renal function causes edema.

Video explanation

Signs and symptoms[edit]

The signs are proteinuria (leakage of protein into the urine), edema (water retention), and hypoalbuminemia (low levels of serum albumin in the blood). Many diseases produce the nephrotic syndrome; minimal change disease is unique because it is the only one lacking any evidence of pathology on light microscopy, hence the name.

When protein is lost in the urine, the concentration of protein in the blood decreases, thereby reducing the intravascular oncotic pressure relative to the interstitial tissue. The subsequent movement of fluid from the vascular compartment to the interstitial compartment manifests as the swelling known as edema. Edema is commonly observed in the feet and legs, particularly in individuals with poorly functioning venous valves, and in the belly or abdomen (ascites), and around the eyes, but can occur anywhere, especially in response to gravity. Additionally, because of this extra fluid that stays in the body, individuals often gain weight and experience fatigue—in many patients, for example, clothes and shoes no longer fit. Some people notice that their urine becomes more frothy or foamy from the excess protein in the urine, and may find that they urinate less often.


For years, pathologists found no changes when viewing specimens under light microscopy, hence the name "minimal change disease." With the advent of electron microscopy, the changes now known as the hallmarks for the disease were discovered. These are diffuse loss of visceral epithelial cells foot processes (i.e., podocyte effacement),[2] vacuolation, and growth of microvilli on the visceral epithelial cells.

The aetiology and pathogenesis of minimal change disease is unclear and is currently considered idiopathic. However, it does not appear to involve complement, immunoglobulins, or immune complex deposition. Rather, an altered cell-mediated immunologic response with abnormal secretion of lymphokines by T cells is thought to reduce the production of anions in the glomerular basement membrane, thereby increasing the glomerular permeability to serum albumin[3] through a reduction of electrostatic repulsion.[4] The loss of anionic charges is also thought to favor foot process fusion.[1] The etiological agent is unclear but viruses such as EBV and food allergies have been implicated. Also, the exact cytokine responsible has yet to be elucidated, with IL-12, IL-18 and IL-13 having been most studied in this regard, yet never conclusively implicated.


Protein tyrosine phosphatase receptor type O, also known as glomerular epithelial protein 1 (GLEPP1), has been shown to be mutated in a number of cases.[5]


Prednisone is prescribed along with a blood pressure medication, typically an ACE inhibitor such as lisinopril. Some nephrologists will start out with the ACE inhibitor first in an attempt to reduce the blood pressure's force which pushes the protein through the cell wall in order to lower the proteinuria. In some cases, a corticosteroid may not be necessary if the case of minimal change disease is mild enough to be treated just with the ACE inhibitor. Often, the liver is overactive with minimal change disease in an attempt to replace lost protein and over produces cholesterol. Therefore, a statin drug is often prescribed for the duration of the treatment. When the urine is clear of protein, the drugs can be discontinued. 50% of patients will relapse and need further treatment with immunosuppressants, such as cyclosporine and tacrolimus.

Minimal change disease usually responds well to initial treatment and over 90% of patients will respond to oral steroids within 6–8 weeks, with most of these having a complete remission.[6] Symptoms of nephrotic syndrome (NS) typically going away; but, this can take from 2 weeks to many months.[6] Younger children, who are more likely to develop minimal change disease, usually respond faster than adults. In 2 out of 3 children with minimal change disease; however, the symptoms of NS can recur, called a relapse, particularly after an infection or an allergic reaction. This is typical, and usually requires additional treatment. Many children experience 3 to 4 relapses before the disease starts to go away. Some children require longer term therapy to keep MCD under control. It appears that the more time one goes without a relapse, the better the chances are that a relapse will not occur. In most children with minimal change disease, particularly among those who respond typically, there is minimal to no permanent damage observed in their kidneys.

With steroid treatment, the symptoms of nephrotic syndrome (NS) will go away, called remission, in the majority of children with minimal change disease. This typically occurs faster, over 2 to 8 weeks, in younger children, but can take up to 3 or 4 months in adults. Typically, the dose of steroids will initially be fairly high, lasting 1or 2 months. When urine protein levels have normalized, steroids are gradually withdrawn over several weeks (to avoid triggering an Addisonian crisis). Giving steroids initially for a longer period of time is thought to reduce the likelihood of relapse. The majority of children with minimal change disease will respond to this treatment.

Even among those who respond well to steroids initially, it is common to observe periods of relapse (return of NS symptoms). 80% of those who get minimal change disease have a recurrence. Because of the potential for relapse, the physician may prescribe and teach the patient how to use a tool to have them check urine protein levels at home. Two out of 3 children who initially responded to steroids will experience this at least once. Typically the steroids will be restarted when this occurs, although the total duration of steroid treatment is usually shorter during relapses than it is during the initial treatment of the disease.

There are several immunosuppressive medications that can be added to steroids when the effect is not sufficient or replace them in case of intolerance or specific contraindications.


Minimal change disease is most common in very young children but can occur in older children and adults. It is by far the most common cause of nephrotic syndrome (NS) in children between the ages of 1 and 7, accounting for the majority (about 90%) of these diagnoses.[7] Among teenagers who develop NS, it is caused by minimal change disease about half the time. It can also occur in adults but accounts for less than 20% of adults diagnosed with NS. Among children less than 10 years of age, boys seem to be more likely to develop minimal change disease than girls. Minimal change disease is being seen with increasing frequency in adults over the age of 80.

People with one or more autoimmune disorders are at increased risk of developing minimal change disease. Having minimal change disease also increases the chances of developing other autoimmune disorders.


Minimal change disease has been called by many other names in the medical literature, including minimal change nephropathy, minimal change nephrosis, minimal change nephrotic syndrome, minimal change glomerulopathy, foot process disease (referring to the foot processes of the podocytes), nil disease (referring to the lack of pathologic findings on light microscopy), nil lesions, lipid nephrosis, and lipoid nephrosis.


  1. ^ a b Kumar V, Fausto N, Abbas A, eds. (2003). Robbins & Cotran Pathologic Basis of Disease (7th ed.). Saunders. pp. 981–2. ISBN 978-0-7216-0187-8. 
  2. ^ "Renal Pathology". Retrieved 2008-11-25. 
  3. ^ "Minimal_change_disease of the Kidney". Retrieved 2008-11-25. 
  4. ^ Mathieson P (2003). "Immune dysregulation in minimal change nephropathy". Nephrol Dial Transplant. 18 (Suppl 6): vi26–9. PMID 12953038. 
  5. ^ Ozaltin F, Ibsirlioglu T, Taskiran EZ, et al. (July 2011). "Disruption of PTPRO causes childhood-onset nephrotic syndrome". American Journal of Human Genetics. 89 (1): 139–47. doi:10.1016/j.ajhg.2011.05.026. PMC 3135805free to read. PMID 21722858. 
  6. ^ a b
  7. ^ Cameron JS (September 1987). "The nephrotic syndrome and its complications". Am. J. Kidney Dis. 10 (3): 157–71. doi:10.1016/s0272-6386(87)80170-1. PMID 3307394. 

External links[edit]